Google
RVPH — REVIVA PHARMACEUTICALS HOLDINGS INC. (Healthcare >> Biotechnology)
RVPH FAQ
What is RVPH's ROE?
REVIVA PHARMACEUTICALS HOLDINGS INC. reports a Return on Equity (ROE) of -95.34%.
What is RVPH's dividend yield?
REVIVA PHARMACEUTICALS HOLDINGS INC. offers a dividend yield of 0.00%.
What is RVPH's Deepscope Quality Score?
Deepscope rates RVPH's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RVPH?
Deepscope's AI Timing Score for RVPH is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RVPH belong to?
REVIVA PHARMACEUTICALS HOLDINGS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.60
Price
-0.01
(-1.68%)
Day Change
|
|
|---|
RVPH, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.60 |
| PBV / Sector |
0.45 / 4.53
GREAT
|
| Earning Per Share | -1.26 |
| PE / Sector |
N/A / 16.80
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
0.34 M
GREAT
|
| Average 1W Daily Value |
0.07 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-03 09:11:31 |
| Symbol | RVPH |
| Name | REVIVA PHARMACEUTICALS HOLDINGS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 13.11 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7.87 / 8,614.17 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10080 N. Wolfe Road, Cupertino, CA, United States, 95014
Phone: 408 501 8881
Website: https://www.revivapharma.com
Sector: Healthcare >> Biotechnology
Description: Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
